Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 40, 2012, Pages 16137-16142

  Fu, Ting ^a   Choi, Sung E ^a   Kim, Dong Hyun ^a   Seok, Sunmi ^a   Suino Powell, Kelly M ^b   Xu, H Eric ^b   Kemper, Jongsook Kim ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Bile acids; Cyp7a1; FGF15; Hepatic metabolism

Indexed keywords

CORECEPTOR BETA KLOTHO; FIBROBLAST GROWTH FACTOR 19; GLYCOGEN SYNTHASE KINASE; KLOTHO PROTEIN; MICRORNA 34A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANIMALS; DNA PRIMERS; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER; LUCIFERASES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICRORNAS; OBESITY; POSTPRANDIAL PERIOD; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

MUS;

EID: 84867068010     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205951109     Document Type: Article

References (38)

1. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438. (Pubitemid 38133916)
2. Inagaki T, et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225.
3. Lin BC, Wang M, Blackmore C, Desnoyers LR (2007) Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 282:27277-27284. (Pubitemid 47501977)
4. Wu X, et al. (2007) Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem 282:29069-29072. (Pubitemid 350043330)
5. Kuro-o M (2008) Endocrine FGFs and Klothos: Emerging concepts. Trends Endocrinol Metab 19:239-245.
6. Kurosu H, et al. (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282:26687-26695. (Pubitemid 47501965)
7. Kir S, et al. (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621-1624.
8. Potthoff MJ, et al. (2011) FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab 13:729-738.
9. Schreuder TC, et al. (2010) The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 298:G440-G445.
10. Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
11. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115:787-798. (Pubitemid 38058492)
12. Neilson JR, Sharp PA (2008) Small RNA regulators of gene expression. Cell 134:899-902.
13. Lee J, Kemper JK (2010) Controlling SIRT1 expression by microRNAs in health and metabolic disease. Aging (Albany NY) 2:527-534.
14. Lee J, et al. (2010) A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J Biol Chem 285:12604-12611.
15. Trajkovski M, et al. (2011) MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474:649-653.
16. Cheung O, et al. (2008) Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48:1810-1820.
17. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating micro- RNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 6:e23937.
18. Li S, et al. (2009) Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 50:1756-1765.
19. Kong L, et al. (2011) Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol 48:61-69.
20. Yamakuchi M, Ferlito M, Lowenstein CJ (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 105:13421-13426.
21. Ito S, et al. (2005) Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Invest 115:2202-2208. (Pubitemid 41134162)
22. Inagaki T, et al. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425. (Pubitemid 46825496)
23. Ogawa Y, et al. (2007) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 104:7432-7437. (Pubitemid 47185923)
24. Badman MK, et al. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426-437. (Pubitemid 46825495)
25. Lovis P, et al. (2008) Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 57:2728-2736.
26. Purushotham A, et al. (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9:327-338.
27. Kemper JK, et al. (2009) FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 10:392-404.
28. Ponugoti B, et al. (2010) SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem 285:33959-33970.
29. Walker AK, et al. (2010) Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev 24:1403-1417.
30. Sawey ET, et al. (2011) Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 19:347-358.
31. He L, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134. (Pubitemid 47014436)
32. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H (2007) Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 104:15472-15477. (Pubitemid 47502941)
33. Kota J, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-1017.
34. Kanamaluru D, et al. (2011) Arginine methylation by PRMT5 at a naturally occurring mutation site is critical for liver metabolic regulation by small heterodimer partner. Mol Cell Biol 31:1540-1550.
35. Miao J, et al. (2009) Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev 23:986-996.
36. Connelly S, Mech C (2004) Delivery of adenoviral DNA to mouse liver. Methods Mol Biol 246:37-52.
37. Esau C, et al. (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3:87-98.
38. Committee on Care and Use of Laboratory Animals (1985) Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda), DHHS Publ No (NIH) 85-23.